Analysts Set Cellectis S.A. (NASDAQ:CLLS) Price Target at $7.00

Shares of Cellectis S.A. (NASDAQ:CLLS) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $7.00.

CLLS has been the subject of a number of recent analyst reports. Barclays initiated coverage on Cellectis in a research report on Thursday, May 28th. They set an “overweight” rating and a $9.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th.

Institutional Trading of Cellectis

Several large investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after purchasing an additional 3,284,409 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Cellectis in the 4th quarter worth about $15,385,000. Citadel Advisors LLC purchased a new position in Cellectis during the 3rd quarter valued at about $633,000. Marshall Wace LLP grew its holdings in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares in the last quarter. 63.90% of the stock is owned by institutional investors.

Cellectis Price Performance

CLLS opened at $3.10 on Friday. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37. The stock’s 50 day simple moving average is $3.03 and its 200 day simple moving average is $3.36. The firm has a market cap of $311.05 million, a price-to-earnings ratio of -4.77 and a beta of 2.92. Cellectis has a 1 year low of $2.35 and a 1 year high of $5.48.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

About Cellectis

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.